课题基金 / 基金详情

BIOMARKER CORE

BIOMARKER CORE
生物标记核心
批准号：
8601648
负责人：
Robert A Rissman
金额：
$21.7万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8601648
关键词：
AccountingAlzheimer&aposs DiseaseAmyloid beta-ProteinApolipoprotein EApplications GrantsBiologicalBiological AssayBiological MarkersCatalogingCatalogsClinical TrialsCognitiveComplementComplexConfidentialityDNADataDrug KineticsEducational process of instructingFloorGenotypeGoalsGrantHigh Pressure Liquid ChromatographyImmunoassayInterventionLaboratoriesMeasurementMeasuresMedicalMethodologyMonitorPatientsPharmaceutical PreparationsPlasmaPlayProceduresProtein AnalysisProteinsProtocols documentationQuality ControlResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResearch ProposalsResourcesRoleSafetySamplingServicesSiteSpecimenSystemTechnical ExpertiseTimeTrainingamyloid peptidebasecompliance behaviorcooperative studyexperiencegenetic analysisinstrumentmedical schoolsmeetingsneuroimagingnovelpre-clinicalscreeningsuccesstau Proteinstau-1

项目摘要

项目成果

Robert A Rissman的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In previous grant cycles, the ADCS has not played a major role in biomarker measurement; assays for Apolipoprotein E (ApoE) genotype, and for plasma and CSF measurement of amyloid peptides and tau proteins have been subcontracted to companies or external academic labs. However, the importance of biomarker measurement has grown steadily, in part due to the success of the Alzheimer's Disease Neuroimaging Initiative. There have been an increasing number of requests for stored ADCS samples, and increasing requests for biomarker measurement from ADCS investigators. To meet these needs, in late 2008, we established a Biomarker Core which is located on the 3rd floor of the Medical Teaching Facility building at UCSD School of Medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HABS-HD - Core D - Omics Core
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease
Neuropathology Core